BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211108
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T223743
CREATED:20210902T200827Z
LAST-MODIFIED:20210902T200827Z
UID:31541-1636329600-1636588799@www.pharmajournalist.com
SUMMARY:LEAP TA Life Sciences
DESCRIPTION:LEAP TA: Life Sciences is a unique open platform for the boldest talent leaders in the industry to engage in genuinely disruptive dialogues. Meet 80+ of your peers to rethink your recruitment approach\, allowing you to find better people faster in an increasingly competitive talent market. \nTaking part in this live online event will help you redefine your processes in an uncertain world\, and successfully navigate the new normal operating environment. \nThis is your opportunity to fill the gap between reading an article and hiring an external consultant to help you solve your own recruitment challenges for the short\, medium\, and long term. \nTo know more visit: https://ter.li/od0sc4
URL:https://www.pharmajournalist.com/event/leap-ta-life-sciences/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211109
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T223743
CREATED:20210820T074956Z
LAST-MODIFIED:20210820T074956Z
UID:31376-1636416000-1636588799@www.pharmajournalist.com
SUMMARY:Biomarkers for Rare Diseases Summit
DESCRIPTION:As reports predict the global biomarker test market will exceed $16bn in coming years\, the ability to identify and utilize predictive\, diagnostic and prognostic biomarkers is a priority for drug developers. In rare disease\, affecting over 400 million worldwide and where clinical insights exist for only around 400 of the 7000+ disease identified\, biomarkers are a valuable tool to accelerate drug development where there is current great unmet need. With this\, we are excited to announce the launch of the inaugural Biomarkers for Rare Diseases Summit. \n \nUniting world leaders developing novel therapeutics for rare disease\, we will discuss learnings\, challenges and future directions at the only summit dedicated to approaches to identify\, test and proof clinical biomarkers in rare disease for regulatory approval. From identifying disease driving biomarkers\, robust assay validation\, harnessing latest technologies and demonstrating therapy efficacy\, we bring you the definitive platform to accelerate bench to bedside rare disease development towards regulatory filing and patient populations. \nTo Know more visit: https://bit.ly/3AX0FIt
URL:https://www.pharmajournalist.com/event/biomarkers-for-rare-diseases-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR